Evidence map›Paper›PMID 41782730›Full record

ArticleAccess microbiology2026

Diversity and clinical correlations of SARS-CoV-2 variant during the introduction of the Delta variant in Guatemala.

Claudia Carranza, Lucia Ortiz, Maria Eugenia Castellanos, Ana Silvia Gonzalez-Reiche, Renata Mendizabal-Cabrera, Zain Khalil, Adriana van DeGuchte, Keith Farrugia, Mariana Herrera, Ernesto Mena and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Access microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Claudia Carranza *Molecular Biology Laboratory, TecniScan de Guatemala S.A., Guatemala City, Guatemala.
Lucia Ortiz *Department of Population Health, Poultry Diagnostic and Research Center, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Maria Eugenia CastellanosCollege of Medicine and Dentistry, James Cook University, Townsville, Australia.ORCID https://orcid.org/0000-0002-8181-6321
Ana Silvia Gonzalez-ReicheDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Renata Mendizabal-CabreraCentro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
Zain KhalilDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adriana van DeGuchteDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Keith FarrugiaDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mariana HerreraMolecular Biology Laboratory, TecniScan de Guatemala S.A., Guatemala City, Guatemala.
Ernesto MenaMolecular Biology Laboratory, TecniScan de Guatemala S.A., Guatemala City, Guatemala.
Celia Cordon-RosalesCentro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.ORCID https://orcid.org/0000-0003-2381-4173
Harm van BakelDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniel R PerezDepartment of Population Health, Poultry Diagnostic and Research Center, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic surveillance is crucial for understanding viral evolution and guiding public health responses. However, many countries, particularly in Central America, have limited sequencing capacity, resulting in scarce and delayed data. This study addresses this gap by analysing 320 SARS-CoV-2 genomes sequenced from a major diagnostic centre in Guatemala City, Guatemala, between April and August 2021. Clade 21J (Delta) was predominant (46.2%), followed by 19B (29.4%) and 20J (Gamma, 6.6%). The most reported symptoms were cough, headache, malaise and myalgia/arthralgia. Among patients infected with the Delta variant, 39.9% reported being contacts from a confirmed case, less than reported by the patients infected with non-Delta variants (53.2%,

Indexed as

Delta variantGuatemalasevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surveillance

Identifiers

PMID41782730
PMCPMC12956025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.